Am a bit surprised the analyst assigned no value to the asset; with no treatment for PSP, there is a route to approval in this rare disease (and we can add CBD too). This should add a few $ to the valuation (given the low POS in the first instance).
AD is more complex and I think combination therapy as articulated by Adam Boxer could be very complex in the real world.
Also the CEO mentioned other potential assets in the CNS space now that POC has been demonstrated. I’m guessing that one of these is against alpha-synuclein for PD.
Agreed on PSP and CBD. Rare, fatal, nothing approved, and the regulatory conversations are already open. That's the fastest route and it should be worth something even at a low probability.
On the synuclein guess, it's already partnered. Novartis licensed ARO-SNCA in August 2025. Which makes it a useful test of your point: the CEO says three more wholly owned CNS candidates enter the clinic within twelve months, so we'll find out soon what the targets are.
Am a bit surprised the analyst assigned no value to the asset; with no treatment for PSP, there is a route to approval in this rare disease (and we can add CBD too). This should add a few $ to the valuation (given the low POS in the first instance).
AD is more complex and I think combination therapy as articulated by Adam Boxer could be very complex in the real world.
Also the CEO mentioned other potential assets in the CNS space now that POC has been demonstrated. I’m guessing that one of these is against alpha-synuclein for PD.
Agreed on PSP and CBD. Rare, fatal, nothing approved, and the regulatory conversations are already open. That's the fastest route and it should be worth something even at a low probability.
On the synuclein guess, it's already partnered. Novartis licensed ARO-SNCA in August 2025. Which makes it a useful test of your point: the CEO says three more wholly owned CNS candidates enter the clinic within twelve months, so we'll find out soon what the targets are.